Invention Grant
- Patent Title: Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
-
Application No.: US17689034Application Date: 2022-03-08
-
Publication No.: US11613751B2Publication Date: 2023-03-28
- Inventor: Lucas D. BonDurant , Mark K. Schlegel , Jeffrey Zuber , Lauren Blair Woods , Tyler Chickering
- Applicant: Alnylam Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Deborah L. Nagle
- Main IPC: C12N15/113
- IPC: C12N15/113
Abstract:
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.
Public/Granted literature
- US20220290153A1 ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF Public/Granted day:2022-09-15
Information query
IPC分类:
